親友來度假 華人大破財

親友來度假 華人大破財


看到這文章就回想起以前住的離紐約市近。只要有誰要來紐約玩。我們就必須奉陪。親友居然說: "花你們越多錢與越多時間，表示我和你們越親。"我們回台灣時，他倒說；"對不起!!要上班恕無法奉陪。"

有的親友更誇張向我們借信用卡猛刷。到時債留給我們付。反正美金比台幣大。就讓我們先付了。到時一聲 " 謝謝啊。兄弟嘛談錢傷感情~" 就不還錢走人了。

有時全家大小，外帶公婆、小叔小嬸。浩浩蕩蕩全部來住上七天七夜。或者為了綠卡不得不打擾一個月。一到暑假親友就來報到。我們大開免費旅館。吃住旅遊全都包。招待唯恐不週。

等多年吃虧上當久了。對這種吃定人的親友也學到會婉轉的說:【真不巧!我們正好那幾天也要出門旅遊。】但是也有那種: "那好我們正好可以一起去玩玩。"或是"那麼改你回來那天才去你家住幾天好啦。"或是"你家那週有客人。那也不要緊。趁機會認識一下你的朋友吧。" 就是有這種不管怎樣都要來看你的親友。真的是嗚呼哀哉!!

http://www.worldjournal.com/view/full_news/22725660/article-%E8%A6%AA%E5%8F%8B%E4%BE%86%E5%BA%A6%E5%81%87-%E8%8F%AF%E4%BA%BA%E5%A4%A7%E7%A0%B4%E8%B2%A1?instance=top_rec

親友來度假 華人大破財

記者駱舒嫻／洛杉磯報導 世界新聞網 北美華人社區新聞

May 28, 2013 09:06 AM | 67623 次 | 14  | 52  |  | 

中國大陸出國旅遊不斷升溫，除了傳統跟團旅遊，越來越多中國觀光客偏愛彈性較高的自助遊。對於在美華人，雖然「有朋自遠方來，不亦悅乎」，但也有人叫苦，親友來美觀光，自己情面難卻，結果成了貼錢貼時間的「地陪」。 「吃住在我家，機場接送、附近旅遊、逛街都是我開車，在外面吃飯我埋單，附近地方旅遊門票都是我掏錢」，南加華人楊先生近期荷包大出血，國內的兄嫂前往密西根州參加完兒子大學畢業典禮，一家三口在全美自助觀光，臨時通知楊先生要來洛杉磯，美其名曰「好久不見」，來看看弟弟一家，但又提出要楊先生陪同遊南加，「找旅行社會被宰」，指名要去迪士尼、影城、聖地牙哥海洋公園、賭城等著名景點和outlets 購物。 楊先生請了一個多禮拜假，帶兄嫂一家玩轉各地，粗略算一筆賬，單是公園、看秀門票一項上花費就逾千元，還不算日益漲價的汽油錢和在外吃飯、住宿開銷，「除了在outlets購物，其他時候都只有我掏錢包的分」，直到把兄嫂一家送上飛機，對方「一句也沒提錢，我也沒好意思提」，兄嫂是雙薪公務員，家庭條件不差，楊先生回國時雖然也請吃飯，「但絕不會包吃、包住，陪我們全家去玩，不明白他們來美國，怎麼就那麼理所當然吃定我」。 家住聖蓋博谷西區的華人主婦王太太抱怨，近年中國大陸來美產子風氣日盛，去年底有喜的小姑子也提出要來南加產子，透過國內中介取得旅遊觀光簽證後，「就要先來看這裡月子中心環境，兼帶旅遊購物，要我們給安排」。近年春節期間小姑來美，吃住全在王太太家，王太太每天除了接送兩個孩子，其他時間就花在開車帶小姑子把聖谷地區十幾家月子中心都看了個遍，或者帶到各處outlets、商場購物。「到稍遠點的outlets去購物，下午總是來不及趕回家接孩子放學，只能找朋友幫忙接」，雖然諸多不便，但礙於小姑子難得來一趟，也不好意思多抱怨，「還要提心吊膽照顧她，生怕出什麼事，這個責任可擔當不起」。 王太太說，小姑子「來的時候什麼也沒帶，婆婆讓她幫我們帶的土特產、茶葉都沒給我們帶來，走的時候卻帶了兩大箱名牌衣服鞋包」，在王太太家中還留了兩箱趁打折時囤積的嬰兒用品，稱「下回來生孩子就可以用了」，「我一想到還有下回，頭都開始大了」。 洛杉磯加大在讀博士生方同學月前突然接到表姊來電話，告知人正在洛杉磯開會，其後有多餘幾天活動時間，要方同學「帶我到處玩玩」。方同學說，原本臨近期末，學業就格外緊張，但與表姊多年未見，一向感情不錯，就撥冗陪同遊玩，結果「充當了三天司機、翻譯和跟班，累得跟狗一樣，吃飯、加油、買票全部我刷卡，表姊看到就跟沒事人一樣，覺得這才算盡地主之誼吧」。 表姊臨走時，還興致勃勃提到近期打算來南加州購置房產，要方同學幫忙「安排安排」，方同學趕緊推說自己對買房一竅不通，「得找房地產中介」，對方緊接一句「到時你得幫我找」，讓方同學頓感「麻煩才剛開始」。 <看更多…回到新聞總覽>

Read more: 世界新聞網-北美華文新聞、華商資訊 - 親友來度假 華人大破財

密碼破解不難 11字以上較強

密碼破解不難 11字以上較強

• 2013-05-29 13:20
• 中央社
• 中央社

　科技網站透過實驗證明，就算是長達16個任意字元所組成的密碼，駭客也能在不到1小時內成功破解。不過網站建議，密碼還是越長越好，且11字元以上的比較安全。
　科技網站Ars Technica從列有1萬6449個密碼的清單當中，破解超過1萬4800組密碼。3名駭客聯手替網站進行這項實驗，成功率為62%到90%，連「qeadzcwrsfxv1331」這種組合也被破解。
　這3名駭客也公布他們如何破解密碼，和破解密碼的傳統手法。
　駭客要猜測密碼時，不是重複在網站上輸入密碼，而是透過網路上取得所謂的「雜湊密碼」（hashed passwords）清單以破解密碼。
　「雜湊」是讓使用者加密前的密碼，透過不可逆演算法產出由數字和字母組成的獨特字串。這樣駭客難以從加密後字串推回到原本的密碼，網站儲存時也是儲存雜湊密碼以加強安全。
　假使雜湊密碼清單遭竊取，有心人士也難以破解原本的密碼，不過網站實驗證實，這非毫無可能。
　其中1名駭客、Stricture Consulting Group的創辦人與執行長葛斯尼（Jeremi Gosney）透過密碼破解手法，解出1萬多組密碼。
　一開始，葛斯尼用「暴力破解法」（Brute-force Attack）破解1到6字元的密碼。
　他透過這種方法，在2分鐘32秒內找出1316組加密前的密碼。葛斯尼又以相同方法，找出1618組7或8字元的密碼。
　第二種破解法是除了暴力破解法之外，再加上「字典攻擊法」（dictionary attack），成為混和式攻擊法。他在5小時又28分鐘內，破解共1萬2935組密碼。
　根據這項駭客實驗，以8字元以下真實詞彙組成的密碼相當容易被破解。Ars Technica建議，為了安全，最好直接用11字元以上的密碼
　Ars Technica說：「讀者應要花時間確定所有密碼最少都是11字元，包含大小寫字母和數字。最好也不要長得像某種模式。」1020529

Teriparatide-Denosumab Combo Strengthens Postmenopausal Bone

Diedtra Henderson

May 15, 2013

 

• 4 comments

http://www.medscape.com/viewarticle/804245 

Editors' Recommendations

• Denosumab Helps Boost BMD After Menopause
• Fracture Healing Appears Unaffected by Denosumab
• Men at Risk for Osteoporosis Should Have DXA Testing

Topic Alert

is already on your Topic Alert list.

• Add Other Topics

Receive an email from Medscape whenever new articles on this topic are available.

• Add Osteoporosis to My Topic Alert

[ Close Window ]

Topic Alert

Thank you for subscribing to Topic Alert.

has been added to your Topic Alert list. You will receive an email when new content is available from Medscape on your selected topics.

  

If you subscribed to this topic in error or wish to manage your Topic Alert list click here.

Drug & Reference Information

• Osteoporosis in Solid Organ Transplantation
• Pediatric Osteoporosis
• Involutional Osteoporosis Imaging

Postmenopausal women with weak bones who took the osteoporosis remedies teriparatide and denosumab in combination, rather than sequentially, had increased bone-mineral density (BMD) after 12 months. The combination has the potential to lower fracture risk, according to an industry-sponsored trial.
Joy N. Tsai, MD, from the Department of Medicine, Endocrine Unit, Massachusetts General Hospital, in Boston, and colleagues report their findings in an article published online May 15 in the Lancet.
According to the National Institutes of Health, some 40 million American women already have osteoporosis or are at high risk of developing the bone disease. The low bone mass and structural deterioration of bone increases the risk of fractures, especially at the hip, spine, and wrist.
Other investigators have tried to increase the value of osteoporosis remedies by testing amino bisphosphonates in combination with teriparatide or parathyroid hormone, but the results have been disappointing.
In the current study, Dr. Tsai and coauthors tested the combination of teriparatide and denosumab, a monoclonal antibody that inhibits osteoclast-mediated bone resorption. They screened 526 women aged 45 years or older who were at high fracture risk, and enrolled 100 into the open-label trial from September 2009 to January 2011. The women received 20 μg teriparatide per day or 60 mg denosumab every 6 months, or both for 12 months. They also took supplemental calcium and vitamin D.
Impressive Results
"In this 12-month randomised, controlled trial we show that combined teriparatide and denosumab increased BMD at the [posterior-anterior lumbar spine], femoral neck, and hip significantly more than either drug alone," the authors write. "Moreover, the 12-month changes in femoral-neck and total-hip BMD in the combination-therapy group (4.2% and 4.9%, respectively) were greater than have been reported with approved therapies for postmenopausal osteoporosis"
In an interview with Medscape Medical News, Ethel Siris, MD, from Columbia University Medical Center, New York-Presbyterian Hospital, New York City, and director of the clinical osteoporosis program, calls the results "impressive."
Today, women at high risk for fracture are given teriparatide to improve the quality and quantity of bone. Then, to preserve those gains, women then get a drug similar to denosumab. "If you don't, whatever you gain will dwindle away," Dr. Siris said.
Building and preserving bone in the hip and the spine by using the therapies in combination is especially significant because fractures there are "devastating," she said. Hip fractures increase mortality and cause spikes in nursing home admissions; spine fractures "make people miserable" and deform the back.
However, Dr. Siris cautions that even though the study was well-executed, it remains just a single study. If the results are confirmed through larger trials and more is learned about the mechanism of action, "that is going to be a wonderful asset to the field," she told Medscape Medical News.
The authors acknowledge that more work needs to be done before the combination is ready for clinical use but are enthusiastic about the findings. "Although studies are needed to assess reductions in fracture risk and to explore the effects of different doses and durations of treatment, the results of this trial suggest that this specific combination of drugs could be a useful option in the treatment of patients with osteoporosis at especially high risk of fracture," they conclude.
The researchers presented an earlier version of the results at the American Society for Bone and Mineral Research (ASBMR) 2012 Annual Meeting.

Financial support for the study was provided by the Harvard Clinical and Translational Science Center; the National Center for Research Resources; Eli Lilly, which manufactures teriparatide; and Amgen, which manufactures denosumab. One study author is a consultant for Eli Lilly, and one coauthor was previously a consultant for Amgen. All authors disclosed receiving or having received research funding from Amgen and Eli Lilly. Dr. Siris is a consultant to Amgen and Eli Lilly.
Lancet. Published online May 15, 2013. Abstract

http://www.medscape.com/viewarticle/804245

The Lancet~Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

   

     

• Home
• |
• Journals
  • The Lancet
  • The Lancet Diabetes & Endocrinology
  • The Lancet Global Health
  • The Lancet Infectious Diseases
  • The Lancet Neurology
  • The Lancet Oncology
  • The Lancet Respiratory Medicine
• |

The Lancet iPad app: Articles in a new light

The Lancet iPad application (app) spans across all Lancet titles including The Lancet, The Lancet Oncology,
The Lancet Neurology and The Lancet Infectious Diseases.

Functionality includes:

• Article-based navigation to find articles quickly
• Download articles for immediate or future use, either on or offline
• Share articles with colleagues
• Annotate articles
• Create alerts
• Bookmark favourites

No, Thanks

outline goes here

The Lancet, Early Online Publication, 15 May 2013

doi:10.1016/S0140-6736(13)60856-9Cite or Link Using DOI

This article can be found in the following collection:

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

Original Text

Joy N Tsai MD a †, Alexander V Uihlein MD a †, Hang Lee PhD b, Ruchit Kumbhani BA a, Erica Siwila-Sackman BA a, Elizabeth A McKay BA a, Sherri-Ann M Burnett-Bowie MD a, Robert M Neer MD a, Dr Benjamin Z Leder MD a

Summary

Background

Osteoporosis medications increase bone-mineral density (BMD) and lower but do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy. We compared combined teriparatide and denosumab with both agents alone.

Methods

From September, 2009, to January, 2011, we enrolled postmenopausal women with osteoporosis into this randomised, controlled trial. Patients were assigned in a 1:1:1 ratio to receive 20 μg teriparatide daily, 60 mg denosumab every 6 months, or both. BMD was measured at 0, 3, 6, and 12 months. Women who completed at least one study visit after baseline were assessed in a modified intention-to-treat analysis. This trial is registered with ClinicalTrials.gov, number NCT00926380.

Findings

94 (94%) of 100 eligible women completed at least one study visit after baseline. At 12 months, posterior-anterior lumbar spine BMD increased more in the combination group (9·1%, [SD 3·9]) than in the teriparatide (6·2% [4·6], p=0·0139) or denosumab (5·5% [3·3], p=0·0005) groups. Femoral-neck BMD also increased more in the combination group (4·2% [3·0]) than in the teriparatide (0·8% [4·1], p=0·0007) and denosumab (2·1% [3·8], p=0·0238) groups, as did total-hip BMD (combination, 4·9% [2·9]; teriparatide, 0·7% [2·7], p<0 2="" denosumab="" p="0·0011).</div">

Interpretation

Combined teriparatide and denosumab increased BMD more than either agent alone and more than has been reported with approved therapies. Combination treatment might, therefore, be useful to treat patients at high risk of fracture.

Funding

Amgen, Eli Lilly, National Center for Research Resources.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60856-9/abstract

骨質疏鬆症的藥物增加骨礦物質密度（BMD）和降低骨折但不完全排除骨折的風險。雙膦酸鹽結合蛋白同化製劑並沒有改善的療效。我們單獨比較teriparatide 和 denosumab 兩種藥物。

方法


從2009年9月至2011年1月，我們參加到這項隨機試驗，對照試驗的是絕經後婦女骨質疏鬆症。患者以1:1:1的比例分配，接受teriparatide每日20微克，每6個月60毫克的denosumab，或兩者兼而有之。對在0，3，6和12個月BMD的測定。婦女完成基線至少有一項研究後的訪問。在修改後的意向性治療做分析評估。這項試驗註冊是ClinicalTrials.gov，NCT00926380號。

發現


100個符合條件的婦女中有94（94％）完成訪問後，至少有一項研究基楚線。在12個月後。在聯合用藥組（9.1％，[SD3.9）比在teriparatide特立帕肽（6.2％[4.6]，P =0.0139）或denosumab狄諾塞麥（5.5％[3.3]，P= 0.0005）前位腰椎骨密度增加。
頸股骨組合用藥組（4.2％[3.0]）比在單用teriparatide特立帕肽者（0.8％[4.1]，P =0.0007）的骨密度也增加了更多。總髖部骨密度也是聯合用藥組骨密度增加了更多，單用denosumab狄諾塞麥（2.1％ [3.8]，P =0.0238）組，（，單用teriparatide特立帕肽，0.7％[2.7]，聯合用藥組合，4.9％[2.9]P <0數據博客逃脫-2 =“數據博客逃脫狄諾塞麥=”“數據博客逃脫-P=0.0011）。</ DIV>

解釋

聯合使用teriparatide特立帕肽和denosumab狄諾塞麥兩種藥可增加骨密度。這比僅單獨使用一種藥物更能增加骨密度。也超過任何已報導批准的治療法。因此，聯合兩種藥治療法可能是對治療高危險性骨折者十分有用的。

研究資金


Amgen公司，禮來，國家研究資源中心。

**********************************************************

Two Drugs Better Than One in Postmenopausal Osteoporosis

By Amy Orciari Herman

Combination therapy with teriparatide and the monoclonal antibody denosumab increases bone mineral density (BMD) to a greater extent than either drug alone in women with postmenopausal osteoporosis, according to an industry-funded study in the Lancet.

Researchers randomized 100 postmenopausal women with high fracture risk to receive subcutaneous teriparatide (daily), denosumab (every 6 months), or both for 1 year. At the end of treatment, posterior-anterior spine BMD had increased significantly more with combination therapy (9% increase from baseline) than with either agent alone (roughly 6% each). Femoral-neck BMD and total-hip BMD had also increased more with combination therapy.

"The BMD changes in the combined-therapy group were greater than have been reported with any approved therapies," the researchers write. They conclude that their findings "suggest that this specific combination of drugs could be a useful option in the treatment of patients with osteoporosis at especially high risk of fracture."

%%%%%%%%%%%%%%%%%%%%%%%

Joy,

 

I received "Physician's First Watch" email everyday and I do read them, selectively on those interest to me or I feel I should know and that will cover most of the articles news.  It is quite interesting that the email of my "Physican's First Watch" and the same one you sent me come together.

 

Reading daily email of article/news alert, and one of them comes from my daughter, I am a mighty proud father! How about that!

 

You're now the "mover" of the trend of osteoporosis treatment, with the bad publicity surrounding on bisphosphonates (which used to be the mainstream of the thrapy or the drug of choice), I think Prolia will take off, along with Forteo, which had been much less commonly used before.

 

Mom went to a piano recital (Mrs. Kisner's students), mom's Chinese student, Jonathan, is the only one playing organ.  Mrs. Kisner lamente that she could have the student like you any more.  And she was talking about your piano and organ; I wish she knew your article published in Lancet!

 

dad

---------- Forwarded message ----------
From: Physician's First Watch <FirstWatch@jwatch.org>
Date: Wed, May 15, 2013 at 7:22 AM
Subject: Pelvic Organ Prolapse Surgery / Doubts on Sodium / Combo Tx for Osteoporosis / More ...
To: JERKATY@gmail.com

To ensure you receive Physician's First Watch, add FirstWatch@jwatch.org to your address book.
	Forward  |  Sign Up  |  My Alerts  |  About Physician's First Watch  |  Editorial Board
Physician's First Watch for May 15, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Effectiveness of Pelvic Organ Prolapse Surgery Deteriorates over Time IOM Report Notes Doubts on Dietary Sodium Recommendations Two Drugs Better Than One in Postmenopausal Osteoporosis Hysterectomy Not Associated with Heightened Cardiovascular Risk Factors Interview: Marathon Bombings' Lessons — Part 2 Featured in Journal Watch: Orlistat Probably Doesn't Cause Acute Liver Injury FDA Approves Oral Solution for Subarachnoid Hemorrhage Effectiveness of Pelvic Organ Prolapse Surgery Deteriorates over Time By Kelly Young Long-term follow-up of pelvic organ prolapse repair reveals a failure rate that increases over time, a JAMA study finds. Some 200 women undergoing abdominal sacrocolpopexy for pelvic organ prolapse were randomized to prophylactic anti-incontinence surgery (Burch urethropexy) or no urethropexy. At 7 years, the probability of pelvic organ prolapse failure was 48% with urethropexy and 34% without urethropexy — not a significant difference. Failure rates gradually increased over the course of the study. Urethropexy reduced the likelihood of stress urinary incontinence. Overall, there was a 10% chance of mesh erosion. The authors conclude, "Women considering abdominal sacrocolpopexy should be counseled that this procedure effectively provides relief from [pelvic organ prolapse] symptoms; however, the anatomic support deteriorates over time." An editorialist writes, "This study has important clinical implications and calls into question the designation of the abdominal sacrocolpopexy as the criterion standard procedure for prolapse repair." JAMA article (Free abstract) JAMA editorial (Subscription required) Background: Journal Watch Women's Health summary of study's early findings (Your Journal Watch registration required) Top IOM Report Notes Doubts on Dietary Sodium Recommendations By Amy Orciari Herman New research supports the health benefits of lowering sodium intake from very high levels to more moderate levels (i.e., 2300 mg/day), according to an Institute of Medicine (IOM) report, but reducing intake too much might actually be detrimental to one's health. Current guidelines recommend a 2300 mg daily limit for those at average risk, and a 1500 mg limit for higher-risk individuals such as blacks, adults over age 50, and those with diabetes or kidney disease. The new IOM report concludes that evidence is insufficient to determine whether lowering intake below 2300 mg raises or lowers cardiovascular risk in the general population. In addition, there's not enough evidence to indicate that higher-risk adults should have lower targets than those at average risk; in fact, some research points to possible harms with lower intake among higher-risk individuals. IOM report (Free) IOM news release (Free) Background: Previous Physician's First Watch coverage of the salt controversy (Free) Top Two Drugs Better Than One in Postmenopausal Osteoporosis By Amy Orciari Herman Combination therapy with teriparatide and the monoclonal antibody denosumab increases bone mineral density (BMD) to a greater extent than either drug alone in women with postmenopausal osteoporosis, according to an industry-funded study in the Lancet. Researchers randomized 100 postmenopausal women with high fracture risk to receive subcutaneous teriparatide (daily), denosumab (every 6 months), or both for 1 year. At the end of treatment, posterior-anterior spine BMD had increased significantly more with combination therapy (9% increase from baseline) than with either agent alone (roughly 6% each). Femoral-neck BMD and total-hip BMD had also increased more with combination therapy. "The BMD changes in the combined-therapy group were greater than have been reported with any approved therapies," the researchers write. They conclude that their findings "suggest that this specific combination of drugs could be a useful option in the treatment of patients with osteoporosis at especially high risk of fracture." Lancet article (Free abstract) Lancet comment (Subscription required) Background: Journal Watch Women's Health summary of previous study on combo therapy with a bisphosphonate (Your Journal Watch registration required) Top Hysterectomy Not Associated with Heightened Cardiovascular Risk Factors By Joe Elia Women who undergo elective hysterectomy experience changes in cardiovascular risk factors similar to those observed after natural menopause, according to a study in the Journal of the American College of Cardiology. The finding contrasts with previous research showing increased risks after hysterectomy. Researchers followed some 2000 women through menopause or elective hysterectomy annually for up to 11 years. Risk factors at baseline and following the final menstrual period were compared between those undergoing surgery (with or without oophorectomy) and natural menopause. Changes were noted in both groups, "but not in a pattern suggesting increasing cardiovascular risk following hysterectomy." The authors conclude that their results "should provide reassurance to women and their clinicians that hysterectomy with or without ovarian conservation in mid-life is not likely to substantially accelerate women's [cardiovascular] risk." Journal of the American College of Cardiology online-first page (Free) Top Interview: Marathon Bombings' Lessons — Part 2 By Joe Elia Clinical Conversations continues its series of brief interviews on the lessons learned from the Boston Marathon bombings. This one is with Alasdair Conn, chief of emergency services at Massachusetts General Hospital. Clinical Conversations podcast (Free) Last week's interview with Dr. Ron Walls (Free) Top Featured in Journal Watch: Orlistat Probably Doesn't Cause Acute Liver Injury By The Journal Watch Editors Risk for liver injury was similar in the 90 days before and 90 days after patients' first prescriptions for orlistat (Alli) in a study published in BMJ. Journal Watch General Medicine summary (Free) Top FDA Approves Oral Solution for Subarachnoid Hemorrhage By The Editors The FDA has approved a nimodipine oral solution (marketed as Nymalize) to treat subarachnoid hemorrhage. The drug was previously only available in gel-capsule form. Regulators say they hope the new oral formulation, which can also be given via nasogastric tube, will reduce medication errors caused by healthcare providers injecting the liquid contents of the nimodipine capsules intravenously. FDA news release (Free) Top Physician Editors contributing to this issue were: David G. Fairchild, MD, MPH, and Richard Saitz, MD, MPH, FACP, FASAM. Physician's First Watch is editorially independent and does not endorse any company, publication, product, or service. This e-mail was sent to: JERKATY@GMAIL.COM Unsubscribe from this alert or update your preferences at My Alerts. Journal Watch: 860 Winter Street, Waltham, MA 02451, USA Copyright © 2013. Massachusetts Medical Society. All rights reserved.